novo nordisk glp-1 receptor agonists weight management diabetes treatments agonist medications The FDA approved a pill version of the GLP Novo Nordisk promotes new GLP-1

Abstract Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment

doi: 10.1177/2042098612446473

Do not use this drug if you or a family member has had: Medullary Thyroid Carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) FDA Adverse Event Reporting To report side effects, visit www.fda.gov/medwatch or call 1-800-FDA-1088

These agents act on multiple physiological pathways involved in type 2 diabetes with the effect of increasing insulin secretion and decreasing glucagon to control glucose levels (1,2)

Persistently elevated glucagon-like peptide-1 levels among critically ill surgical patients after sepsis and development of chronic critical illness and dismal long-term outcomes